Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
Pictures can be worth a thousand medical words and can help increase drug compliance, so new pictograms on medicine packaging have been launched in the Netherlands. A wider EU roll-out is anticipated.
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...
Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...
An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Correspondence to Professor Susumu Kusunoki, Department of Neurology, Kindai University Faculty of Medicine, 377+2 Ohno+Higashi, Osaka+Sayama, Osaka, 589+8511 Japan; kusunoki-tky{at}umin.ac.jp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback